Puration Announces $3 Million Annual Revenue Business Plan Update Presentation Scheduled Tuesday June 6th

DALLAS, June 1, 2017 /PRNewswire/ --

Puration, Inc. (USOTC: PURA) today announced an online, on-demand presentation to be available on the company's website next Tuesday, June 6th. The purpose of the presentation is to present updates of the company's business plan and plan to build $3 million in annual revenue. The updates stem from the impending acquisition of the controlling interest in PURA by American Cannabis Innovations Conglomerated ('ACI'). The acquisition is anticipated to be finalized prior to the update presentation. The presentation will include updates to the company's ongoing contract with Alkame Holdings, Inc. (USOTC: ALKM). The presentation will also include updates to PURA's ongoing business relationship with North American Cannabis Holdings, Inc. (USOTC: USMJ). Furthermore, the presentation will include new developments with the Company's ongoing work with NCM Biotech.

PURA Market Capitalization Improvements Summary - No Reverse or Forward Split 

The common stock of PURA will remain traded on the OTC Markets with no forward or reverse split taking place in conjunction with the ACI transaction. ACI expects the potential for market capitalizations of PURA to improve by transitioning the company toward better investment structures, with better terms that are altogether better suited to the current and more mature stage of development. For instance, PURA recently announced a substantial convertible debt elimination in conjunction with the pending ACI transaction in addition to a $10 million funding commitment.

ACI Business Plan 

ACI is a private equity backed rollup founded to combine a variety of leading young cannabis companies with complimentary offerings and synergistic operations. PURA and USMJ are the first of five acquisitions in the cannabis sector ACI has planned for the near future. ACI is seeking to acquire early stage, undervalued businesses with intellectual properties validated by market tests, and commercial or consumer sales. ACI expects to improve the operating efficiency of acquired assets by streaming redundant functions and leveraging complimentary functions.

Learn More About PURA: http://www.purationinc.com/.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Media Contact:
Puration Contact:
Brian Shibley
CEO
[email protected]
+1-214-937-9097

SOURCE Puration, Inc.